Buprenorphine

Major

Buprenorphine Ramelteon Rozerem Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ranitidine Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Ranolazine Aspruzyo Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Rasagiline Azilect Explained An increased risk of serotonin syndrome or opioid-related toxicity Details Buprenorphine Relacorilant Lifyorli Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Buprenorphine Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Buprenorphine Remifentanil Explained Increased risk of CNS and respiratory depression, profound sedation, hypotension, coma and death, reduced analgesic effect or prec... Details Buprenorphine Remimazolam Byfavo Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Remoxipride Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Revumenib Revuforj Explained An increased risk of QT interval prolongation Details Buprenorphine Ribociclib Kisqali Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Rifabutin Mycobutin Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Rifampin Rifadin Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Rifapentine Priftin Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Rilpivirine Edurant Explained An increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Risperidone Perseris Explained An increased risk of QT interval prolongation Details Buprenorphine Ritonavir Norvir Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Rizatriptan Explained An increased risk of serotonin syndrome Details Buprenorphine Ropeginterferon Alfa-2B-Njft Besremi Explained Increased risk of sedation Details Buprenorphine Schisandra Sphenanthera Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Scopolamine Pamine Explained Increased or potentiated scopolamine effects, an increased risk of CNS depression and an increased risk of paralytic ileus Details Buprenorphine Secobarbital Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Selegiline Anipryl Explained An increased risk of serotonin syndrome or opioid-related toxicity Details Buprenorphine Selpercatinib Retevmo Explained Increased risk of QT interval prolongation Details Buprenorphine Sertindole Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Sertraline Explained Increased risk of serotonin syndrome and an increased risk of QT interval prolongation Details Buprenorphine Sevoflurane Petrem Explained An increased risk of QT interval prolongation, reduced sevoflurane (MAC) exposure needed to produce anesthesia and an increased ri... Details Buprenorphine Sibutramine Explained An increased risk of serotonin syndrome Details Buprenorphine Siponimod Mayzent Explained An increased risk of QT interval prolongation Details Buprenorphine Sodium Oxybate Lumryz Explained An increased risk of CNS depression and clinically significant respiratory depression, obtundation, hypotension, profound sedation... Details Buprenorphine Sodium Phosphate OsmoPrep Explained An increased risk of QT interval prolongation Details Buprenorphine Sodium Phosphate, Dibasic Explained An increased risk of QT interval prolongation Details Buprenorphine Sodium Phosphate, Monobasic Explained An increased risk of QT interval prolongation Details Buprenorphine Solifenacin Vesicare Explained An increased risk of paralytic ileus and an increased risk of QT interval prolongation Details Buprenorphine Sorafenib Nexavar Explained An increased risk of QT interval prolongation Details Buprenorphine Sotalol Betapace Explained An increased risk of QT interval prolongation Details Buprenorphine Spironolactone Aldactone Explained Reduced efficacy of diuretics Details Buprenorphine St John's Wort Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of serotonin syndrome Details Buprenorphine Stramonium Explained An increased risk of paralytic ileus Details Buprenorphine Sufentanil Dsuvia Explained Reduced analgesic effect of SUFentanil and an increased risk of serotonin syndrome Details